# Study of the Safety and Immune Response of Two Serogroup B Meningococcal Vaccines Administered to Healthy Adolescents

> **NCT00297817** · PHASE2 · COMPLETED · sponsor: **Novartis Vaccines** · enrollment: 203 (actual)

## Conditions studied

- Meningococcal Disease

## Interventions

- **BIOLOGICAL:** serogroup B meningococcal vaccine
- **BIOLOGICAL:** serogroup B meningococcal vaccine
- **BIOLOGICAL:** serogroup B meningococcal vaccine

## Key facts

- **NCT ID:** NCT00297817
- **Lead sponsor:** Novartis Vaccines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** 2007-04
- **Final completion:** 2007-04
- **Target enrollment:** 203 (ACTUAL)
- **Last updated:** 2016-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00297817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00297817, "Study of the Safety and Immune Response of Two Serogroup B Meningococcal Vaccines Administered to Healthy Adolescents". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00297817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*